#1 Clinical Trials Search in Europe

Lovo-A

This article discusses the ongoing clinical trials of Lovo-A, a component of the innovative immunotherapy drug STC-1010. The trials aim to evaluate the safety and effectiveness of this treatment for patients with advanced or metastatic colorectal cancer. STC-1010 is being tested in combination with standard-of-care therapies to potentially improve outcomes for patients with this challenging disease.

Table of Contents

What is LOVO-A?

LOVO-A is an innovative immunotherapy treatment being studied for patients with advanced colorectal cancer. It is part of a new drug called STC-1010, which is a combination of different cell therapies[1]. LOVO-A is one of the six active substances in STC-1010, along with HCT116-A, HCT116-B, HT-29-A, HT-29-B, and LOVO-B[1].

Medical Conditions Treated

LOVO-A, as part of STC-1010, is being studied to treat unresectable locally advanced or metastatic colorectal cancer[1]. This means it’s intended for patients whose cancer:

  • Has spread to nearby tissues or lymph nodes and cannot be completely removed by surgery (locally advanced)
  • Has spread to distant parts of the body (metastatic)
  • Cannot be surgically removed (unresectable)

How LOVO-A Works

LOVO-A is a type of cell therapy, which is an advanced form of treatment that uses cells to fight diseases[1]. In this case, LOVO-A is derived from colorectal cancer cells[1]. The idea behind this treatment is to stimulate the patient’s immune system to recognize and attack cancer cells more effectively.

STC-1010, which includes LOVO-A, is given as a solution for injection, typically administered into the skin (intradermal injection)[1]. It’s used in combination with other cancer treatments to potentially enhance their effectiveness.

Clinical Trial Details

LOVO-A is currently being studied in a clinical trial called the BreAK CRC trial[1]. This trial has two main parts:

  1. Phase I: This part focuses on finding the right dose and checking the safety of STC-1010 when given with standard cancer treatments[1].
  2. Phase IIA: This part looks at how well STC-1010 works in treating colorectal cancer when combined with standard treatments[1].

The trial is testing STC-1010 (which includes LOVO-A) in combination with other cancer drugs like mFOLFOX6 (a chemotherapy combination) and bevacizumab (a targeted therapy)[1].

Eligibility Criteria

To participate in this study, patients must meet certain criteria. Some key points include:

  • Age between 18-75 years[1]
  • Diagnosed with unresectable locally advanced or metastatic colorectal cancer[1]
  • Good overall health status[1]
  • No active autoimmune diseases or severe infections[1]

There are additional specific criteria for different parts of the study. Your doctor can provide more detailed information about eligibility.

Potential Benefits and Risks

As with any experimental treatment, there are potential benefits and risks to consider:

Potential Benefits:

  • Access to a new treatment that might be more effective than standard therapies
  • Close monitoring by healthcare professionals
  • Contributing to medical research that could help future patients

Potential Risks:

  • Unknown side effects
  • The treatment may not be effective for everyone
  • Time commitment for medical visits and procedures

It’s important to discuss these potential benefits and risks thoroughly with your healthcare provider before considering participation in the clinical trial.

Aspect Details
Drug Name STC-1010 (including Lovo-A)
Type of Treatment Immunotherapy (Cell therapy)
Target Condition Unresectable locally advanced or metastatic colorectal cancer
Trial Phase Phase I/IIA
Main Objectives Assess safety, determine optimal dose, evaluate efficacy
Combination Therapy Used with standard chemotherapy (mFOLFOX6) and bevacizumab
Patient Groups MSS/pMMR and MSI-H/dMMR colorectal cancer patients
Primary Endpoint Progression-free survival rate at 12 months (Phase IIA)

FAQ

  • What is Lovo-A and how does it work? Lovo-A is one of the active substances in STC-1010, an immunotherapy drug being tested for colorectal cancer. It's a type of cell therapy designed to stimulate the immune system to fight cancer cells.
  • Who is eligible for the clinical trials involving Lovo-A? The trials are primarily for adults aged 18-75 with unresectable locally advanced or metastatic colorectal cancer. Specific eligibility criteria include factors like overall health status, lab test results, and prior treatments.
  • How is Lovo-A administered in the clinical trials? Lovo-A, as part of STC-1010, is administered as a solution for injection. It's given along with standard chemotherapy treatments and other medications like bevacizumab.
  • What are the main goals of the clinical trials using Lovo-A? The trials aim to determine the safety of STC-1010 (which includes Lovo-A), find the right dose, and assess its effectiveness in treating advanced colorectal cancer when combined with standard treatments.
  • Are there any specific side effects associated with Lovo-A? The trials are designed to monitor for side effects. While specific side effects of Lovo-A are not mentioned, the study closely watches for any adverse events related to the treatment combination.

Ongoing Clinical Trials on Lovo-A

  • Study on STC-1010 and Drug Combination for Patients with Advanced or Metastatic Colorectal Cancer

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France

Glossary

  • Unresectable: A tumor that cannot be removed completely through surgery.
  • Metastatic: Cancer that has spread from its original site to other parts of the body.
  • Immunotherapy: A type of cancer treatment that helps the body's immune system fight cancer cells.
  • Standard-of-care (SOC): The best known treatment currently used for a specific condition or disease.
  • mFOLFOX6: A combination chemotherapy regimen used to treat colorectal cancer.
  • Bevacizumab: A targeted therapy drug used in combination with chemotherapy for colorectal cancer treatment.
  • MSS/pMMR: Microsatellite stable/proficient mismatch repair, describing certain characteristics of colorectal cancer cells.
  • MSI-H/dMMR: Microsatellite instability-high/deficient mismatch repair, another set of characteristics found in some colorectal cancers.
  • RECIST 1.1: Response Evaluation Criteria in Solid Tumors, a standard way to measure how well a cancer patient responds to treatment.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives without the cancer getting worse.

References

  1. http://clinicaltrials.eu/trial/study-on-stc-1010-and-drug-combination-for-patients-with-advanced-or-metastatic-colorectal-cancer/